April 20, 2026 10:50–11:08 AM
Broadway 3
Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.
Our strategy pairs genetics-based patient selection with validated biomarkers to enable efficient clinical studies and an orphan, accelerated-approval path.
